Pfizer receives FDA approval for Nivestym, a Neutropenia biosimilar
Pfizer Inc. has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for Nivestym (filgrastim-aafi), a biosimilar to Amgen’s Neupogen (filgrastim), for treating neutropenia. This approval is a crucial step in making effective treatments more accessible and affordable for patients suffering from this condition. Neutropenia, characterized by an unusually low […]